 |
 |
Business Wire (press release) BW5584 SEP 04,2003 10:47 PACIFIC 13:47 EASTERN ( BW)(FL-IVAX)(IVX)(IVX.L) IVAX Receives Final Approval For Pergolide Business Editors/Health/Medical Writers MIAMI--(BUSINESS WIRE)--Sept. 4, 2003--IVAX Corporation (AMEX:IVX) (LSE:IVX.L) announced today that it has received final approval for its Abbreviated New Drug Application (ANDA) for pergolide mesylate tablets in .05 mg, .25 mg and 1 mg dosage strengths and has begun marketing these tablets through the company's wholly owned subsidiary, IVAX Pharmaceuticals, Inc. Pergolide mesylate is the generic equivalent of Permax(R) tablets marketed by Amarin Corporation PLC for use as an adjunctive treatment in connection with Parkinson's disease. U.S. sales of Permax during 2002 were approximately $50 million. Pergolide mesylate tablets' active pharmaceutical ingredient is produced at IVAX' facility in the Czech Republic, which will also be manufacturing the tablets. IVAX continues its aggressive program to increase the number of products in its generic portfolio. IVAX Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and brand equivalent (generic) pharmaceuticals and veterinary products in the U.S. and internationally. Copies of this and other news releases may be obtained free of charge from IVAX' website at http://www.ivax.com. Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties which may affect the company's business and prospects, including the risks that launch of pergolide mesylate tablets in .05 mg, .25 mg and 1 mg strengths may be delayed; changing market conditions; the availability and cost of raw materials and other third party products; the impact of competitive products and pricing; and other risks and uncertainties based on economic, competitive, governmental, technological and other factors discussed in the Company's Annual Report on Form 10-K and its other filings with the Securities and Exchange Commission. Permax(R) is a registered trademark of Eli Lilly and Company. --30--JD/mi* CONTACT: IVAX Corporation, Miami David Malina, 305-575-6043 KEYWORD: FLORIDA INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL PRODUCT SOURCE: IVAX Corporation SOURCE: Business Wire (press release) http://tinyurl.com/mc9g * * * ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn